Marizyme, Inc. (MRZM)

0.0533 0.0000 (0.00%) As of 11:05AM EDT. Market open.

Marizyme, Inc.

555 Heritage Drive
Suite 205
Jupiter, FL 33458
United States
(561) 935-9955
https://www.marizyme.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David L. Barthel M.B.A.	CEO, Secretary & Director	350k	N/A	1958
Mr. George Kovalyov C.A., CPA	CFO, Treasurer & Director	168k	N/A	1985
Dr. Catherine J. Pachuk Ph.D.	Executive VP & Chief Scientific Officer	325k	N/A	1957
Dr. Claudio Rigatto M.D.	Chief Medical Officer of My Health Logic	N/A	N/A	N/A
Kari Jacobson	Controller	N/A	N/A	N/A
Mr. Harrison Albert Ross C.F.A.	Vice President of Finance	N/A	N/A	1993

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures. Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.

Corporate governance

Marizyme, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.